OXFORD GLOBAL

9th Annual
# Cell Culture & Bioprocessing
Congress

06 - 07 October 2020 | London, UK

## Day 1 Stream 1 | Cell Line Engineering – Ensuring Stability, Quality & Clonality

- Improving efficiency and removing bottlenecks in cell line development
- Strategies to boost productivity in cell line development
- Clone selection strategies and establishing clonality
- Enhancing CHO engineering
- Targeted approaches to engineering cell lines
- Improving stability of cell lines

## Day 1 Stream 2 | Upstream & Downstream Bioprocessing

- Process automation, modelling & digitalisation
- High throughput technologies in bioprocessing
- Improving instrumentation for biopharmaceutical drug production
- Reducing timelines in bioprocessing
- Analysing and monitoring processes to ensure quality
- Managing critical raw materials
- Facilitating technology transfer for cell-based products

## Day 2 Stream 1 | Innovative Techniques & Technologies For Cell Line Development

- High purity cell culture for therapeutic development
- Next-Gen strategies for improving processes
- Cell line generation for viral vector production

**Focus Session: Genomic Strategies & CRISPR for Cell Line Development**

- Genomic cell line characterisation & validation
- Stem cell models for personalised therapies

## Day 2 Stream 2 | Cell & Gene Therapy Bioprocessing

- Upstream innovations in cell & gene therapy bioprocessing
- Novel downstream processing for cell & gene therapy
- Scalability of cell & gene therapy products
- Cryopreservation and critical raw material management and procurement
- Supply chain

## Day 2 Stream 3 | Optimising Cell Culture Technology & Media

- Strategies for greater productivity when cultivating cells
- High cell density perfusion culture
- Cell culture media analysis & development
- Advanced cell culture techniques & technologies for 3D models
- **Workshop: Organoid Development**
  - Organoids as new models to study human development and disease
  - Challenges, limitations and promise of organoids
  - Case studies in kidney, pancreas and brain organoids
  - Tissue engineering & 3D Bioprinting

## Benefits to Attending

✓ **Hear from and meet with key cell culture and bioprocessing innovators.** 2020 attendees include: Vice President, UCB Pharma; Vice President, Sanofi and Director, Cell Culture Development, Boehringer Ingelheim

✓ **Discuss collaborative solutions to early and late stage cell line development.** This year's congress will bring key figures together to address the latest advances in cell line engineering, genomic tools and stability in cell lines

✓ **Discover the latest technologies impacting upstream and downstream bioprocessing,** from single use technologies to process automation, modelling & digitalisation

✓ **Benefit from in-depth case studies encompassing** the latest developments in optimising cell culture technology and media, including a workshop on the challenges, limitations and priorities of organoids in cell culture

✓ **An exclusive session on Cell & Gene Therapy Bioprocessing** allows you to brainstorm collaborative solutions to the challenges of working with advanced therapies, including supply chain, logistics and scalability

✓ **Unparalleled networking opportunities:** The two-day congress offers dedicated networking breaks creating an interative platform for scientific discussions and 1-2-1 meetings. The exhibition hall and poster presentation spaces offer a relaxed and professional environment for discussion

✓ This event is part of our flagship **Cell Series UK**, which also includes our co-located **7th Annual Regenerative Medicine & Advanced Therapy Development** and **6th Annual Cell & Gene Therapy Manufacturing Congresses**

### 2020 Speakers Include:

Stefan Haider
Boehringer Ingelheim

Stefanos Grammatikos
UCB Pharma

Ron Bates
Bristol-Myers Squibb

### Meet Senior Decision Makers

450 VPs, Directors & Heads from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event. Delegate job titles include:

| | |
|---|---|
| Cell Line Engineering | Downstream Processing |
| Cell Culture | Organoid Development |
| Upstream Processing | Cell Line Development |

### Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

| | |
|---|---|
| Bioprocessing Solutions | Cell Culture Media |
| Instruments & Consumables | Genomic Technologies |
| Cell Line Development Solutions | Automation |

**For booking details & registration fees please refer to the final page or visit:** https://www.oxfordglobal.co.uk/cell-series-uk/

**2020 Confirmed & Reserved Speakers:**

- Stefanos Grammatikos, Vice President, Head of Biotech Sciences, UCB Pharma
- Tony D'Amore, Vice President, Product Research & Development, Sanofi Pasteur
- Joachim Bär, Director, Cell Culture Development, Boehringer Ingelheim
- Ron Bates, Director, Bristol-Myers Squibb
- Mark Yang, Director, Sanofi
- Stefan Haider, Associate Director, Upstream Development, Boehringer Ingelheim
- Jonathon Orme, Global Head of Cell Banking, AstraZeneca
- Uwe Demelbauer, Global Head Drug Substance Development, Operational Sciences Mammalian, Novartis
- Hans Keirstead, Chief Executive Officer, Aivita Biomedical
- Benoit Moreaux, Chief Scientific and Technological Officer, Bone Therapeutics
- Alan Smith, Executive Vice President, Technical Operations, Bellicum Pharmaceuticals
- Bo Kara, Vice President, Process Development, Evox Therapeutics
- Erin Kimbrel, Executive Director of Regenerative Medicine, Astellas
- David Kim, Director, Global Supply Chain, Kite Pharma
- Dan Miskimin, Technical Director, Juno Therapeutics
- Kyle Grant, Associate Director of Vector Production, Voyager Therapeutics
- Jolanda Gerritsen, Assistant Director, Cell Line Development, Genmab
- Carmen Brenner, Associate Director Quality, Bone Therapeutics
- Ulrich Ruemenapp, Head of Launch Preparation and Coordination, Bayer AG
- Laurence Guianvarc'h, Head of Upstream Process Development, Novartis
- Andreas Unsöld, Head of Cell Culture Media, Boehringer Ingelheim
- Maria del Pilar Redondo, Site Head, Cell Therapy Technology Center, Takeda Madrid
- Sharon Longhurst, Head of CMC, Immunicum
- Mark Chen, Manager, Cell Line Development, Cell and Gene Therapy Product Development, GlaxoSmithKline
- Angeliki Grammenos, Manager Regulatory, Celyad
- Vincent Dewar, Lead Monoclonal Antibodies Platform, Senior Manager, GlaxoSmithKline
- Rolf Köhler, Group Head CLD1, Novartis
- Simon Ausländer, Group Leader, Molecular & Cell Line Development, F. Hoffman-La Roche Ltd
- Rahul Pradhan, Group Leader, Kymab
- David Moss, Group Leader, Process Development, Adaptimmune
- Seshu Tyagarajan, CMC Team Leader, Novartis
- Daniele Perna, Associate Fellow, Investigator Disruptive Technologies, GlaxoSmithKline
- Saurabh Sen, Principal Scientist, Boehringer Ingelheim
- Rhiannon David, Microphysiological Systems Scientific Lead, Clinical Pharmacology and Safety Sciences, AstraZeneca
- Yuval Shimoni, Principal Engineer, Bayer AG
- Benjamin Moritz, Principal Scientist – Process Sciences, Ichnos Sciences SA
- Asli Akidil, Senior Scientist, Oncology Safety Combinations, AstraZeneca
- Britta Anderson, Senior R&D Scientist, Biopharmaceutical Expression Systems Team, Merck KGaA
- Jonathan Collins, Senior Downstream Process and Technical Transfer Expert, Manufacturing Science and Technology, Novartis
- Aline Hughson, Senior Process Scientist, Gyroscope Therapeutics
- Mona Bausch, Scientist, Perfusion / Cell Culture Media, Merck KGaA
- Manuel Carrondo, Vice President, iBET-Instituto de Biologia Experimental e Tecnologica
- Jenny Murray, Past Chair, International Serum Industry Association (ISIA)
- Lydia Teboul, Head of Molecular and Cellular Biology, MRC Harwell Institute
- Stefan Przyborski, Professor of Cell Technology, Durham University
- Dusko Ilic, Professor of Stem Cell Science, King's College London
- William James, Professor of Virology, University of Oxford
- David James, Professor of Bioprocess Engineering, University of Sheffield
- Hugo Vankelecom, Professor, University of Leuven
- Mohamed Essameldin Abdelgawad, Associate Professor of Cellular, Molecular & Industrial Biotechnology, Helwan University, Cairo, Egypt; Visiting Professor/Group Leader at Inserm U1197, Paris Saclay University, France

**2020 Cell Series UK Confirmed Sponsors Include:**

**2020 Gold Sponsors**

**2020 Silver Sponsor**

**2020 Bronze Sponsors**



**2020 Networking & Presentation Sponsors**

If you're on Twitter, make sure to follow us @CellCultureConf and join the congress conversation on #CellSeries20

For more information please contact marketing@oxfordglobal.co.uk

**9th Annual Cell Culture & Bioprocessing Congress**
**Day One – Tuesday 6th October 2020**

| | | |
|---|---|---|
| **07.30 – 08.20** | **Registration** | |
| **08.20 – 08.25** | **Oxford Global's Welcome Address** | |
| **08.25 – 08.30** | **Chairman's Opening Address** | |
| **08.30 – 09.00** | **Keynote Address: Bioprocessing Innovations In The Era Of Clinical Acceleration And Process Intensification**<br>• Current trends in clinical development acceleration and bioprocess intensification impose an unprecedented compression of CMC development timelines and new bioprocessing challenges downstream of the cell culture bioreactor<br>• In this talk I will present a series of innovations we have introduced, some incremental and some potentially disruptive, while rising to the latest challenges of bio CMC development and bioprocessing<br><br>**Stefanos Grammatikos, Vice President, Head of Biotech Sciences, UCB Pharma** | |
| | **Cell Line Engineering – Ensuring Stability, Quality & Clonality** | **Upstream & Downstream Bioprocessing** |
| **09.00 – 09.30** | **Stream Keynote Address: Removing Bottlenecks In Cell Line Development**<br><br>**Rolf Köhler, Group Head CLD1, Novartis** | **Stream Keynote Address: Modelling Of Bioprocesses**<br><br>**Joachim Bär, Director, Cell Culture Development, Boehringer Ingelheim** |
| **09.30 – 10.00** | **Gold Solution Provider Presentation**<br>MOLECULAR DEVICES | **Gold Solution Provider Presentation**<br>SCIEX |
| **10.00 – 11.20** | **Morning Coffee & Refreshments, One To One Meetings x4, Poster Presentation Sessions** | |
| **11.20 – 11.50** | **An Overview Of CHO Cell Line Development And Cell Engineering At Roche**<br><br>**Simon Ausländer, Group Leader, Molecular & Cell Line Development, F. Hoffman-La Roche Ltd** | **Hard Lessons Learned Throughout A Legacy Cell Culture Process**<br><br>**Ron Bates, Director, Bristol-Myers Squibb** |
| **11.50 – 12.20** | **Increased Productivities In Recombinant CHO Cell Lines**<br><br>**Benjamin Moritz, Principal Scientist – Process Sciences, Ichnos Sciences SA** | **Process Automation, Modelling & Digitalisation**<br><br>**Stefan Haider, Associate Director, Upstream Development, Boehringer Ingelheim** |
| **12.20 – 12.50** | **Bronze Solution Provider Presentation**<br>BERKELEY LIGHTS | **Silver Solution Provider Presentation**<br>eppendorf |
| **12.50 – 13.50** | **Lunch, One To One Meetings x3, Poster Presentation Sessions** | |

**9th Annual Cell Culture & Bioprocessing Congress**
**Day One – Tuesday 6th October 2020**

| | Cell Line Engineering – Ensuring Stability, Quality & Clonality | Upstream & Downstream Bioprocessing |
|---|---|---|
| **13.50 – 14.20** | **BioEnhance: When Large Molecules Meet Small Molecules**<br><br>**Daniele Perna, Associate Fellow, Investigator Disruptive Technologies, GlaxoSmithKline** | **Perspectives Of Vaccine Development And Manufacture**<br><br>**Tony D'Amore, Vice President, Product Research & Development, Sanofi Pasteur** |
| **14.20 – 14.50** | **Accelerating Cell Line Development By Combining The CHOZN® GS Platform With UCOE® Technology**<br><br>**Britta Anderson, Senior R&D Scientist, Biopharmaceutical Expression Systems Team, Merck KGaA** | **Production Of Monoclonal Antibodies As Immunotools In The Vaccine Industry, A Case Study: Methods Performance Analysis And Product Comparability**<br>• Monoclonal antibodies (mAbs) at GSK Vaccine<br>• Evolution of in vitro production over the last 6 years<br>• Description of methods in place<br>• Method performance (hybridoma vs transient infection)<br>• Characterization plan: CQA comparability<br>• Conclusions<br><br>**Vincent Dewar, Lead Monoclonal Antibodies Platform, Senior Manager, GlaxoSmithKline** |
| **14.50 – 15.20** | **Solution Provider Presentation**<br><br>**For Sponsorship Opportunities Please Contact**<br>**sponsorship@oxfordglobal.co.uk** | **Solution Provider Presentation**<br><br>ADVANCED INSTRUMENTS |
| **15.20 – 16.20** | **Afternoon Coffee & Refreshments, One To One Meetings x3, Poster Presentation Sessions** | |
| **16.20 – 16.50** | **A Response Plan To Viral Contamination In A Bioproduction Facility**<br><br>**Yuval Shimoni, Principal Engineer, Bayer AG** | **Strategic Collaboration And Effective Technology Transfer In CMC Development**<br>• The challenges with outsourcing CMC development and manufacturing of biologics<br>• Best practices for successful CDO or CMO partnerships<br>• Understanding the success factors, and mitigating the risks<br>• Good contract making, and how to protect your IP?<br>• Effective technology & knowledge transfer<br><br>**Ulrich Rumenapp, Head of Launch Preparation and Coordination, Bayer AG** |
| **16.50 – 17.20** | **Cell Line Engineering From A Regulatory Perspective**<br><br>**Angeliki Grammenos, Manager Regulatory, Celyad** | **Technology Transfer And Process Development**<br><br>**Rahul Pradhan, Group Leader, Kymab** |
| **17.20 – 17.50** | **Synthetic Biology Platform Development For CHO Cell Design And Engineering**<br><br>**David James, Professor of Bioprocess Engineering, University of Sheffield** | **Big Data For Downstream Processing**<br><br>**Uwe Demelbauer, Global Head Drug Substance Development, Operational Sciences Mammalian, Novartis** |

**9th Annual Cell Culture & Bioprocessing Congress**
**Day One – Tuesday 6th October 2020**

| | Cell Line Engineering – Ensuring Stability, Quality & Clonality | Upstream & Downstream Bioprocessing |
|---|---|---|
| **17.50 – 18.20** | **Title TBC**<br><br>**Reserved: Lisa Pieper, Head of Laboratory – Cell Culture Development, Boehringer Ingelheim** | **Bulk Freezing Process Development**<br><br>**Mark Yang, Director, Sanofi** |
| **18.20 – 18.50** | **Accelerating Cell Line Development: Stem Cell Differentiation**<br><br>**Reserved: Arifa Naeem, Senior Research Scientist, MeiraGTx** | **Managing Critical Raw Materials**<br><br>**Sharon Longhurst, Head of CMC, Immunicum** |
| **18.50 – 19.20** | *Delegates are welcome to attend the co-located presentations* | **Case Studies In Downstream Processing**<br><br>**Jonathan Collins, Senior Downstream Process and Technical Transfer Expert, Manufacturing Science and Technology, Novartis** |
| **19.20** | **Networking Drinks & End Of Day One** | |

# 9th Annual Cell Culture & Bioprocessing Congress
## Day Two – Wednesday 7th October 2020

| | 9th Annual Cell Culture & Bioprocessing Congress | | |
|---|---|---|---|
| **08.00 – 09.30** | **Workshop: Strategies For Ensuring Efficient Cell Line Development For Drug Development**<br><br>**Moderator: Kyle Grant, Associate Director of Vector Production, Voyager Therapeutics** | | |
| | **Innovative Techniques & Technologies For Cell Line Development** | **Cell & Gene Therapy Bioprocessing** | **Optimising Cell Culture Technology & Media** |
| **09.30 – 10.00** | **Stream Keynote Address: Novel Immunotherapy Targeting Tumor Initiating Cells**<br><br>• 72% 2-year survival, 54% 5-year survival in stage 3 recurrent and stage 4 cancer<br>• 96% manufacturing success rate<br>• Extremely low cost of goods<br><br>**Hans Keirstead, Chief Executive Officer, Aivita Biomedical** | **Stream Keynote Address: Cell & Gene Therapy Bioprocessing**<br><br>**Benoit Moreaux, Chief Scientific and Technnological Officer, Bone Therapeutics** | **Stream Keynote Address: Moving Beyond Chemically Defined: Development Strategies To A Functionally Defined Cell Culture Media**<br>This presentation will show the development strategy and results from a chemically defined to a functionally defined cell culture media and give an overview about the used methods and approaches to improve the robustness of cell culture processes over scales. In a first way all media components were clustered into the main groups e.g. amino acids, organic acids, salts, trace metals. The different groups were optimized according the complexity of the raw materials, the solubility, the availability and their necessity for the cells with complex DoE approaches. The results were transferred into a new formulation and the final media was characterized with cell culture studies and newly established analytical methods like 2D Fluorescence Spectroscopy and Dynamic Multiple Reaction Monitoring via LC-MS. The overall achievement is a high performing, less reactive and easy to scale cell culture media which improves process robustness, product yield and also product quality.<br><br>**Andreas Unsöld, Head of Cell Culture Media, Boehringer Ingelheim** |
| **10.00 – 10.30** | Solentim | **Silver Or Above Solution Provider Presentation**<br><br>**For Sponsorship Opportunities Please Contact**<br>**sponsorship@oxfordglobal.co.uk** | **Silver Or Above Solution Provider Presentation**<br><br>**For Sponsorship Opportunities Please Contact**<br>**sponsorship@oxfordglobal.co.uk** |
| **10.30 – 11.30** | **Morning Coffee & Refreshments, One To One Meetings x3, Poster Presentation Sessions** | | |

**9th Annual Cell Culture & Bioprocessing Congress**
**Day Two – Wednesday 7th October 2020**

| | Innovative Techniques & Technologies For Cell Line Development | Cell & Gene Therapy Bioprocessing | Optimising Cell Culture Technology & Media |
|---|---|---|---|
| **11.30 – 12.00** | **Development, Scale-Up And Characterisation Of Engineered Exosome Therapeutic Products**<br><br>**Bo Kara, Vice President, Process Development, Evox Therapeutics** | **Patient-Centric Supply Chain**<br><br>**David Kim, Director, Global Supply Chain, Kite Pharma** | **Organoid And 3D Microphysiological Systems For The Improvement Of Pre-Clinical Safety Assessments**<br>• Human-sourced 3D organoids and microphysiological systems (MPS) provide an opportunity to generate safety and efficacy data for drug development with improved clinical relevance over more traditional 2D cell culture and animal models<br>• I will outline context of use of organoids and MPS at AstraZeneca and provide examples of data generated from these systems that demonstrate the utility of such models for safety assessment<br><br>**Rhiannon David, Microphysiological Systems Scientific Lead, Clinical Pharmacology and Safety Sciences, AstraZeneca** |
| **12.00 – 12.30** | **Generation Of Pluripotent Stem Cell Lines**<br><br>**Erin Kimbrel, Executive Director of Regenerative Medicine, Astellas** | **Methods For Upstream Production**<br><br>**Kyle Grant, Associate Director of Vector Production, Voyager Therapeutics** | **The Development And Application Of Bone Marrow-On-A-Chip Platform For The Preclinical Safety Assessment Of Oncology Compounds**<br><br>**Asli Akidil, Senior Scientist, Oncology Safety Combinations, AstraZeneca** |
| **12.30 – 13.00** | **Solution Provider Presentation**<br>METABOLON | **Solution Provider Presentation**<br><br>**For Sponsorship Opportunities Please Contact sponsorship@oxfordglobal.co.uk** | **Solution Provider Presentation**<br><br>**For Sponsorship Opportunities Please Contact sponsorship@oxfordglobal.co.uk** |
| **13.00 – 14.00** | **Lunch, One To One Meetings x2, Poster Presentation Sessions** | | |

**9th Annual Cell Culture & Bioprocessing Congress**
**Day Two – Wednesday 7th October 2020**

| | Innovative Techniques & Technologies For Cell Line Development | Cell & Gene Therapy Bioprocessing | Optimising Cell Culture Technology & Media |
|---|---|---|---|
| **14.00 – 14.30** | **Stable Cell Line Generation For Viral Vector Production For Cell And Gene Therapy**<br><br>**Mark Chen, Manager, Cell Line Development, Cell and Gene Therapy Product Development, GlaxoSmithKline** | **Novel Downstream Processing Solutions For Cell And Gene Therapy**<br><br>**Manuel Carrondo, Vice President, iBET-Instituto de Biologia Experimental e Tecnologica** | **Workshop: Organoid Development**<br>• Organoids as new models to study human development and disease<br>• Challenges, limitations and promise of organoids<br>• Case studies in kidney, pancreas and bone marrow organoids<br>• Tissue engineering & 3D Bioprinting<br><br>**Moderator: Invitation To: Rob Vries, Chief Executive Officer, Hubrecht Organoid Technology**<br>**Participant: Rhiannon David, Microphysiological Systems Scientific Lead, Clinical Pharmacology and Safety Sciences, AstraZeneca** |
| **14.30 – 15.00** | **Cell Line Development & Upstream Processing**<br><br>**Jolanda Gerritsen, Assistant Director, Cell Line Development, Genmab** | **Strategies For Cell Therapy Development**<br><br>**Maria del Pilar Redondo, Site Head, Cell Therapy Technology Center, Takeda Madrid** | |
| **15.00 – 15.30** | **Optimising In Vitro Biochemical And Cell-Based Assays**<br><br>**Jonathon Orme, Global Head of Cell Banking, AstraZeneca** | **Preclinical Development Of An AAV Vector For Drug Development**<br><br>**Laurence Guianvarc'h, Head of Upstream Process Development, Novartis** | **Endometrial Organoids**<br><br>**Hugo Vankelecom, Professor, University of Leuven** |
| **15.30 – 16.00** | **Afternoon Coffee & Refreshments, One To One Meetings x3, Poster Presentation Sessions** | | |

**9th Annual Cell Culture & Bioprocessing Congress**
**Day Two – Wednesday 7th October 2020**

| | Focus Session: Genomic Strategies & CRISPR For Cell Line Development | Cell & Gene Therapy Bioprocessing | Optimising Cell Culture Technology & Media |
|---|---|---|---|
| **16.00 – 16.30** | **Validation Of Genetic Alterations To Cell Lines**<br><br>**Lydia Teboul, Head of Molecular and Cellular Biology, MRC Harwell Institute** | **Quality Sourcing & Procurement Of GMP Materials For Cell Therapies**<br><br>**Alan Smith, Executive Vice President, Technical Operations, Bellicum Pharmaceuticals** | **Upstream Process Intensification Including Media Development For N-1 Perfusion**<br><br>**Mona Bausch, Scientist, Perfusion / Cell Culture Media, Merck KGaA** |
| **16.30 – 17.00** | **Full Thickness Skin Models From Human Pluripotent Stem Cells For Identification And Testing Effectiveness Of Personalized Therapies In Atopic Dermatitis**<br><br>**Dusko Ilic, Professor of Stem Cell Science, King's College London** | **CMC Project Management In Cell And Gene Therapy Space**<br><br>**Seshu Tyagarajan, CMC Team Leader, Novartis** | **An Introduction To The Tools Available To Determine Suitability Of Serum In Cell Culture**<br><br>**Jenny Murray, Past Chair, International Serum Industry Association (ISIA)** |
| **17.00 – 17.30** | *Delegates are welcome to attend the co-located presentations* | **Design Of An Autologous Cell Therapy Facility**<br><br>**Dan Miskimin, Technical Director, Juno Therapeutics** | **Simpler, Cheaper, Defined, Open-Source And Increasingly Physiological. Rational Developments In The Media For Differentiating Macrophage/Microglia And Neurons From hiPSC**<br><br>**William James, Professor of Virology, University of Oxford** |
| **17.30 – 18.00** | *Delegates are welcome to attend the co-located presentations* | **Quality Control And Bioprocess Analytics For Allogeneic Products**<br><br>**Carmen Brenner, Quality Associate Director, Bone Therapeutics** | **Harnessing An Innovative Completely Chemically Defined, Xeno-Free, Albumin-Free, Protein-Free Controllable Cellular Microenvironment(s) For Expansion/Maintenance Of Human Stem/Progenitor Cells For Production Of ATMPs And Cell-Therapy Applications**<br><br>**Mohamed Essameldin Abdelgawad, Associate Professor of Cellular, Molecular & Industrial Biotechnology, Helwan University, Cairo, Egypt; Visiting Professor/Group Leader at Inserm U1197, Paris Saclay University, France** |
| **18.00 – 18.30** | *Delegates are welcome to attend the co-located presentations* | **Vector Purification: Issues And Challenges With Currently Available Technologies**<br><br>**David Moss, Group Leader, Process Development, Adaptimmune** | *Delegates are welcome to attend the co-located presentations* |
| **18.30 – 19.00** | *Delegates are welcome to attend the co-located presentations* | **Suspension Platform Development And Tech Transfer**<br><br>**Aline Hughson, Senior Process Scientist, Gyroscope Therapeutics** | *Delegates are welcome to attend the co-located presentations* |
| **19.00** | **End Of Congress** | | |

# Cell Series UK

## 9th Annual Cell Culture & Bioprocessing Congress | 7th Annual Regenerative Medicine & Advanced Therapy Development Congress | 6th Annual Cell & Gene Therapy Manufacturing Congress

06 - 07 October 2020 | Novotel London West, London, UK
www.oxfordglobal.co.uk/cell-series-uk/

HOW TO REGISTER:
FAX your booking form to +44(0)1865 689120 | PHONE on +44(0)1865 248455 | EMAIL: marketing@oxfordglobal.co.uk

## Delegate Details

Please complete fully and clearly. Please photocopy for additional delegates.

Please tick which event(s) in the series you are interested in:

☐ Cell Culture ☐ Regenerative Medicine

☐ Cell Therapy Manufacturing

Title:____ Forename:_____ Surname:_____

Job Title:_____

Company/Organisation:_____

Email:_____

Address:_____

Postcode: _____

Country: _____

Direct Telephone _____ Direct Fax: _____

Mobile: _____ Switchboard: _____

Signature: _____ Date: _____

## Registration Fees: 3 events in 1

I would like to attend: (Please tick as appropriate)
*Please note these early registration prices are available until 31st March 2020*

**Industry Delegates (Biopharma, Pharma or Biotech Companies)**

☐ 2-day pass £799 plus VAT

1-day pass £599 plus VAT
☐ Day 1
☐ Day 2

**Academic Delegates**

☐ 2-day pass £550 plus VAT

1-day pass £399 plus VAT
☐ Day 1
☐ Day 2

**Vendor Delegates**
(CROs, Consultants, Technology and Service Providers)

☐ Series Only £1750 plus VAT

☐ Poster Presentation £250 plus VAT

**PROMOTIONAL LITERATURE DISTRIBUTION**

☐ Distribution of your company's promotional literature to all series attendees £999 plus VAT

## Terms & Conditions of Booking

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate:

**Delegate Booking Fee**
The Delegate Booking Fee includes: lunches and refreshments throughout the series, presentations and panel sessions, scheduled one-to-one meetings and networking/social events, series and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser.

An admin surcharge of £50 plus VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online.

Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility.

**Acceptance of a Complimentary Pass**
If you are offered a free delegate pass and you are unable to attend the series, you may nominate a substitute of equal standing (in terms of business and financial responsibility). A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in advance in order to avoid a non-attendance charge of £200 plus VAT being applied.
Your complimentary delegate place is not officially confirmed until we have had chance to check that you qualify for the complimentary pass. Please do not make any travel arrangements before we have confirmed acceptance of your application. We will not be liable for any expenses incurred.

**Delegate Registration Form**
Each Delegate must complete the online delegate registration form issued by the Organiser on receipt of the Delegate Booking Form. This information will only be used for the organisation of the series, for material produced for Delegates and Sponsors and to facilitate the networking sessions.

**Cancellation and Curtailment**
If a Registered Delegate is unable to attend the series, he/she may nominate a substitute of equal standing within their Company. A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in advance in order to avoid cancellation charges being applied. Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation.

| | |
|---|---|
| More than 6 months prior | 35% cancellation fee / 65% refund |
| Between 6 and 3 months prior | 75% cancellation fee / 25% refund |
| Less than 3 months prior to the event | Full cancellation fee / No refund |

**Data Protection**
The data controller is the organiser (Oxford Global Marketing Ltd). The Organiser may disclose such personal information as name, company, job title, telephone and email address to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Series.
Registration details will be retained and used in accordance with our privacy policy.
If you wish to opt out please email info@oxfordglobal.co.uk

**Miscellaneous**
The Organiser will determine the scope and content of series events, seminars, workshops and activities throughout the series.
The Organiser reserves the right to cancel the series without liability to Delegate's Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this series, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded.
For promotional purposes, there may be professional photography and video production taking place during the series. Delegates who do not wish to be filmed or recorded should advise the organisers by email to operations@oxfordglobal.co.uk prior to the event.
These terms and conditions are binding upon the delegate submitting a registration form.

☐ **I agree to the above Terms and Conditions**

## Documentation

I cannot attend but would like to purchase access to the following:

☐ Access to the online conference presentations £499 plus VAT

VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.

## How to Pay

### Number of delegates:

Industry del(s) ☐ Academic dels(s) ☐ Vendor dels(s) ☐

☐ **Special Offer: BUY ONE GET ONE FREE**
*Offer is only valid on the congress and for those registering at Industry or Academic rates*

### Please choose one of the following payment options:

☐ **CREDIT CARD:**

An Oxford Global representative will contact you directly following return of contract / booking form to process card payment.
If payment will be made by a colleague within your company, please complete the following;

Card Payment Contact Name: _____

Phone Number: _____

☐ **INVOICE:**

Invoice Address (if different from above) _____

_____

_____

*Please note there is a £50 plus VAT handling charge for payment via invoice